BR100 Increased By (0.49%)
BR30 Increased By (0.14%)
KSE100 Increased By (0.42%)
KSE30 Increased By (0.42%)
AGHA 7.74 Decreased By ▼ -0.01 (-0.13%)
BECO 5.19 No Change ▼ 0.00 (0%)
BML 57.95 Decreased By ▼ -0.71 (-1.21%)
BOP 34.10 Increased By ▲ 0.41 (1.22%)
CNERGY 10.48 Decreased By ▼ -0.13 (-1.23%)
CSIL 5.42 Increased By ▲ 0.12 (2.26%)
FCCL 54.90 Increased By ▲ 1.16 (2.16%)
FFL 16.68 Increased By ▲ 0.22 (1.34%)
FNEL 1.25 Increased By ▲ 0.03 (2.46%)
KEL 7.40 Increased By ▲ 0.12 (1.65%)
KOSM 5.76 Increased By ▲ 0.12 (2.13%)
LOTCHEM 29.55 Decreased By ▼ -0.10 (-0.34%)
MLCF 95.49 Decreased By ▼ -0.87 (-0.9%)
NBP 203.49 Decreased By ▼ -0.04 (-0.02%)
NCPL 57.75 Increased By ▲ 0.90 (1.58%)
NPL 68.90 Increased By ▲ 1.59 (2.36%)
OGDC 317.50 Decreased By ▼ -0.72 (-0.23%)
PACE 10.70 Increased By ▲ 0.07 (0.66%)
PAEL 42.85 Increased By ▲ 1.08 (2.59%)
PIBTL 16.83 Increased By ▲ 0.02 (0.12%)
PPL 220.75 Increased By ▲ 0.58 (0.26%)
PRL 50.62 Increased By ▲ 1.57 (3.2%)
PTC 70.69 Increased By ▲ 0.68 (0.97%)
SSGC 28.31 Decreased By ▼ -0.83 (-2.85%)
TBL 9.84 Increased By ▲ 0.07 (0.72%)
TELE 8.85 Increased By ▲ 0.03 (0.34%)
TPL 18.25 Increased By ▲ 1.08 (6.29%)
TPLP 12.90 Increased By ▲ 0.39 (3.12%)
TREET 22.78 Increased By ▲ 0.19 (0.84%)
TRG 59.92 Decreased By ▼ -0.30 (-0.5%)
World

Britain has secured 50mn doses of vaccines for new variants: Hancock

  • He said Britain had entered into a partnership with the manufacturer CureVac to develop vaccines that could be quickly adapted as new strains were identified.
Published Updated
By

LONDON: Britain has agreed a initial supply of 50 million doses of vaccines for new variants, Heath Secretary Matt Hancock said on Monday, although he added that evidence showed the shots already being deployed had some effect against the mutations.

"The evidence is that the existing vaccines have some effect against new variants, particularly preventing serious illness and mortality," Hancock told a news briefing on Monday.

He said Britain had entered into a partnership with the manufacturer CureVac to develop vaccines that could be quickly adapted as new strains were identified.

"We've agreed an initial supply of 50 million doses to add to the 400 million doses that are already in our vaccine portfolio," he said.

Comments

Comments are closed for this article.